Traditional Chinese medicine composition for treating fetomaternal blood group incompatibility and preparation method thereof

Abstract

The invention belongs to the field of traditional Chinese medicines, relates to a traditional Chinese medicine composition and a preparation method thereof, and in particular relates to a traditional Chinese medicine composition for treating fetomaternal blood group incompatibility and a preparation method thereof. In order to overcome the existing technical problems of relatively high hepatotoxicity and poor curative effect of the current chemical medicines for treating the fetomaternal blood group incompatibility, the traditional Chinese medicine composition for treating or preventing the fetomaternal blood group incompatibility comprises the following components: 10-50 parts of epimedium, 10-20 parts of oriental wormwood, 5-20 parts of angelica sinensis, 5-15 parts of honeysuckle, 5-10 parts of the root of kudzu vine, 5-15 parts of poria cocos, 5-15 parts of lotus leaf, 1-10 parts of cassia twig, 5-15 parts of wolfberry, 9-15 parts of astragalus membranaceus, 9-15 parts of felwort, 5-15 parts of mint, 1.5-9 parts of radix ophiopogonis, 5.5-15 parts of radix paeoniae alba, 6-9 parts of spatholobus suberctu and 10-15 parts of liquorice. The traditional Chinese medicine composition has an excellent treatment effect in the aspect of treating or preventing the fetomaternal blood group incompatibility, and has low medical side effect and remarkable clinical popularization value.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to a traditional Chinese medicine composition for treating maternal-infant blood type incompatibility and a preparation method thereof. Background technique [0002] Maternal-fetal blood incompatibility (hemolytic disease of the newborn, HDN) is an immune hemolytic disease caused by the difference in blood type between mother and fetus, and it is common in ABO blood group and Rh blood group. The pathogenesis is basically the same. Influenced by immune factors such as blood transfusion, miscarriage, and pregnancy in the past, the pregnant woman produces blood group antibodies against the paternal source, and IgG antibodies can cross the placenta and enter the fetus to destroy red blood cells. The clinical manifestations are miscarriage, stillbirth, heart failure Failure, neonatal hyperbilirubinemia, and even bilirubin encephalopathy have extremely high mortality rates and neurolog...

AI Technical Summary

Problems solved by technology

The traditional treatment methods for maternal-fetal blood group incompatibility are mainly infusion during pregnancy, oral Chinese medicine, postpartum neonatal blue light irradiation, albumin intravenous infusion and exchange transfusion, and have achieved certain curative effect, but there are still some pregnant women who have received drug treatment. Antibody titers and serological indicators have not been significantly improved

Images